Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).

Abstract excerpt

Plasma levels of high-sensitivity C-reactive protein (hsCRP) are an important predictor of cardiovascular disease, and achievement of lower targets of hsCRP with rosuvastatin treatment was associated with improved cardiovascular outcomes. The aim of this study was to examine whether hsCRP levels...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to C-Reactive Protein
• Share to Cholesterol, HDL
• Share to Coronary Disease